Jim Cramer: Buy Johnson & Johnson and Pharmacyclics, and 2 More Stock Picks

Jim Cramer made the following calls on November 11th, 2013. What do you think about his picks?

Johnson & Johnson (NYSE:JNJ): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on October 23, 2013. The stock’s 52-week high is $94.64, and its 52-week low is $68.51. Cramer had positive feelings about Johnson & Johnson, pointing to the company’s partnership with Pharmacyclics on the cancer drug ibrutinib. He said that he thinks that the drug will be approved by the FDA, which will be sure to send share prices of both companies higher.

JNJ 20131111

Pharmacyclics Inc. (NASDAQ:PCYC): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on November 4, 2013. The stock’s 52-week high is $143.34, and its 52-week low is $48.87. Cramer was very enthusiastic about Pharmacyclics, pointing to the company’s partnership with Johnson & Johnson on the cancer drug ibrutinib. He said that he thinks that the drug will be approved by the FDA, which will be sure to send share prices of both companies higher.

PCYC 20131111

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on November 5, 2013. The stock’s 52-week high is $319.83, and its 52-week low is $141.01. As some skeptics begin to think that Wall Street gains will have to roll back by the year’s end, Cramer pointed to company’s such as Regeneron as names that will continue to perform. He said that growth stocks, like some of the hottest names in Biotech, are a great place to be looking toward the year’s end.

REGN 20131111

Skyworks Solutions Inc. (NASDAQ:SWKS): Jim Cramer ranked this stock a Sell. Cramer previously ranked this stock a Sell on February 5, 2013. The stock’s 52-week high is $26.46, and its 52-week low is $19.25. Cramer had mixed feelings about Skyworks Solutions, a manufacturer of semiconductors that often make their way into wireless products. On the one hand, the company reported a great quarter. On the other hand, many on Wall Street are panicking about the sector in general. This implies that, while the company could present value at a later point in time, now was not the time to buy into the stock, simply because there is too much risk due to shaky sentiments about the sector.

SWKS 20131111

Don’t Miss: Big Pharma and Big Tobacco Won’t Control the Marijuana Industry.

More from The Cheat Sheet